Reprieve Cardiovascular Secures $61M in Series B Funding to Revolutionize Heart Failure Care

Reprieve Cardiovascular, Inc. is excited to announce a significant milestone in its mission to revolutionize heart failure care, having raised a remarkable $61,000,000 in its latest funding round. This key achievement not only fuels the company’s ongoing commitment to innovation but also reinforces its position as a pioneering force in the medical device industry. Headquartered in Milford, Massachusetts, Reprieve Cardiovascular is dedicated to developing groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients worldwide. The newly secured funds will be instrumental in accelerating the advancement of its pioneering technologies, including the Reprieve Decongestion Management System. This innovative system is designed to bring intelligence to decongestion management, enabling safer and more efficient fluid removal for patients suffering from heart failure. Building on the promising outcomes of its FASTR Trial pilot study initiated in 2022—which rigorously compared decongestive therapy administered by the Reprieve system with Optimal Diuretic Therapy in patients with acute decompensated heart failure—the company is poised to expand its clinical efforts and further validate its approach through larger-scale studies. The fresh capital injection will enhance research and development initiatives, streamline regulatory processes, and support strategic partnerships, all aimed at hastening the time to market for these life-changing therapies. With this funding announcement, Reprieve Cardiovascular reaffirms its dedication to transforming heart failure treatment paradigms, promising to deliver safer, more effective options for patients in dire need. This support not only highlights investor confidence in the company's visionary approach but also represents a hopeful stride toward a future where heart failure is managed more intelligently and compassionately.